Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

CAR-T Therapies Resource Center

Featured

Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Ajeet Gajra, MD, FACS
Videos
Barriers to CAR-T Therapy Utilization Among Community Hematologists/Oncologists in the US
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
Impact of CAR-T Therapy on Quality of Life: Patient-Reported Outcomes vs Performance-Based Metrics
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
Real-World Treatment With CAR-T Therapies Among Patients With DLBCL
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Conference Coverage
Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting
12/08/2021

Janelle Bradley

Janelle Bradley
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the...
12/08/2021
Journal of Clinical Pathways
News
HCRU and End-of-Life Outcomes Among Patients Receiving CAR-T Therapy
08/05/2021
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study...
08/05/2021
Journal of Clinical Pathways
CAR T-Cell Therapy: Current Practice and Future Solutions to Optimize Patient Access
CAR T-Cell Therapy: Current Practice and Future Solutions to Optimize Patient Access
03/15/2021
Praveen Ramakrishnan Geethakumari, MD
Binod Dhakal, MD
Dheepthi Perumal Ramasamy, BS
Ankit J Kansagra, MD
Praveen Ramakrishnan Geethakumari, MD, and colleagues address clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.
Praveen Ramakrishnan Geethakumari, MD, and colleagues address clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.
Praveen Ramakrishnan...
03/15/2021
Journal of Clinical Pathways
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
Videos
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
12/20/2020
12/20/2020
Journal of Clinical Pathways
News
Real-World CAR-T Therapy Toxicity in Patients With DLBCL
11/11/2020
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring...
11/11/2020
Journal of Clinical Pathways
News
Tisagenlecleucel Yields Comparable Safety, Efficacy in Real-World and Trial Settings
11/11/2020
11/11/2020
Journal of Clinical Pathways
News
Multivariable Score Helps Predict Risk of Neurotoxicity After CAR-T Therapy
10/22/2020
10/22/2020
Journal of Clinical Pathways

Expert Insights

Ajeet Gajra, MD, FACS
Videos
Barriers to CAR-T Therapy Utilization Among Community Hematologists/Oncologists in the US
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
Impact of CAR-T Therapy on Quality of Life: Patient-Reported Outcomes vs Performance-Based Metrics
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
Real-World Treatment With CAR-T Therapies Among Patients With DLBCL
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
Videos
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
12/20/2020
12/20/2020
Journal of Clinical Pathways
Editor Insights
CAR-T Reimbursement Levels Set by CMS, So Where Should Patients Be Treated?
04/19/2018

Winston Wong, PharmD

Winston Wong, PharmD
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
Will payers push for services to...
04/19/2018
Journal of Clinical Pathways
Guest Blog
Why Payers, Other Stakeholders Should Remain Optimistic About CAR-T Therapies
03/15/2018

Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP

Bruce A Feinberg, DO, and Chadi Nabha...
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
Bruce A Feinberg, DO, and Chadi...
03/15/2018
Journal of Clinical Pathways
Editor Insights
The CAR-T Breakthrough: More Than Just Another Treatment Option
02/02/2018

Winston Wong, PharmD

Winston Wong, PharmD
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
While CAR T-cell therapies fill...
02/02/2018
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
08/07/2024
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Farrukh Awan, MD
Videos
Chronic Lymphocytic Leukemia Treatment Updates
07/31/2024
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some...
07/31/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Why People Should Care About How Health Care Works (Part 1)
07/29/2024
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part...
07/29/2024
Cancer Care Business Exchange
Ivy Altomare, MD
Videos
Characteristics of Clinical Trials in Community Oncology Practices Across the US
07/23/2024
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an...
07/23/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Show Me the Medical Evidence
07/15/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health...
07/15/2024
Cancer Care Business Exchange
Gunjan Sharma
Interview
Leveraging Data to Enhance Patient Care: Addressing Social Determinants of Health in Oncology Care
07/10/2024
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst...
07/10/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways

Newsfeed

Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
News
HCRU and End-of-Life Outcomes Among Patients Receiving CAR-T Therapy
08/05/2021
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study...
08/05/2021
Journal of Clinical Pathways
News
Real-World CAR-T Therapy Toxicity in Patients With DLBCL
11/11/2020
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring...
11/11/2020
Journal of Clinical Pathways
News
Tisagenlecleucel Yields Comparable Safety, Efficacy in Real-World and Trial Settings
11/11/2020
11/11/2020
Journal of Clinical Pathways
News
Multivariable Score Helps Predict Risk of Neurotoxicity After CAR-T Therapy
10/22/2020
10/22/2020
Journal of Clinical Pathways
News
Outcomes of CAR-T vs Alternate Therapies for DLBCL in the Real-World Setting
10/22/2020
10/22/2020
Journal of Clinical Pathways
News
Regulating the Use of CAR-T Therapy Outside of the Drug Paradigm
09/22/2020
09/22/2020
Journal of Clinical Pathways
News
Economic Model Estimates Total Costs of Tisagenlecleucel Treatment for ALL
09/11/2020
09/11/2020
Journal of Clinical Pathways
News
CMS Proposes New System for Calculating CAR-T Therapy Reimbursement Rates
08/24/2020
The Centers for Medicare and Medicaid Services (CMS) proposed a new system for calculating reimbursement rates for hospitals administering chimeric antigen receptor T-cell (CAR-T) therapies. Under the new policy,...
The Centers for Medicare and Medicaid Services (CMS) proposed a new system for calculating reimbursement rates for hospitals administering chimeric antigen receptor T-cell (CAR-T) therapies. Under the new policy,...
The...
08/24/2020
Journal of Clinical Pathways
News
CMS Hospital IPPS Proposed Rule Includes CAR-T Reimbursement Updates
05/13/2020
The Centers for Medicare & Medicaid Services (CMS) has released its proposed Hospital Inpatient Prospective Payment System (IPPS) rule for 2021. Included in the proposed rule is a new Medicare Severity-Diagnosis...
The Centers for Medicare & Medicaid Services (CMS) has released its proposed Hospital Inpatient Prospective Payment System (IPPS) rule for 2021. Included in the proposed rule is a new Medicare Severity-Diagnosis...
The...
05/13/2020
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: What Are the Total Costs Associated With Tisagenlecleucel for ALL?
09/17/2020
09/17/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022

Katie Herman

Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Ajeet Gajra, MD, FACS
Videos
Barriers to CAR-T Therapy Utilization Among Community Hematologists/Oncologists in the US
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
Impact of CAR-T Therapy on Quality of Life: Patient-Reported Outcomes vs Performance-Based Metrics
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
Real-World Treatment With CAR-T Therapies Among Patients With DLBCL
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Conference Coverage
Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting
12/08/2021

Janelle Bradley

Janelle Bradley
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the...
12/08/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement